Ingen Technologies, Inc. – ‘8-K’ for 12/1/06

On:  Tuesday, 12/5/06, at 12:09pm ET   ·   For:  12/1/06   ·   Accession #:  1019687-6-2959   ·   File #:  0-28704

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                         3     11K 
 2: EX-99.1     Miscellaneous Exhibit                                  6     29K 
 3: EX-99.2     Miscellaneous Exhibit                                  4     27K 

8-K   —   Current Report

8-K
1st Page of 3
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): December 1, 2006              

INGEN TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)

     Georgia                  000-28704               88-0429044
     -------                 -----------              ----------
(State or other jurisdiction of     (Commission           (I.R.S. Employer    
incorporation or organization)      File Number)        Identification Number)

35193 Avenue "A", Suite-C, Yucaipa, California                 92399          
----------------------------------------------                 -----          
(Address of principal executive offices)                  (Zip Code)    

(800) 259-9622
--------------
(Registrant's telephone number, including area code)

Not Applicable
 (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to           
simultaneously satisfy the filing obligation of the registrant under any of the 
following provisions (see General Instruction A.2. below):                      

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)                                                                        

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR  
240.14a-12)                                                                     

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))                                                       

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))                                                       

8-K
2nd Page of 3
TOC
1st
Previous
Next
↓Bottom
Just 2nd
1.01     Entry into a Material Definitive Agreement                             

Ingen Technologies, Inc. ("Ingen" or the "company") signed two
agreements dated December 1, 2006; one for the distribution of OxyView(TM) and  
and the other for Secure Balance(TM) distribution:                              

       A.       A Distribution Agreement with MedOx Corporation ("MedOx"), a
                 California company, for domestic and global representation of
                  the company's OxyView(TM) product on a "best efforts" basis is
             one of the two agreements. MedOx is entitled to 4% of all
             OxyView(TM) revenues received by Ingen. If MedOx sells at
               least one million OxyView(TM) units, the company will issue
               two million shares of our restricted common stock. MedOx is
          also receiving a cash fee of $10,000 per month for six
                consecutive months commencing in December of 2006. MedOx has
          the right to set the customer price and receives 4% of
                revenues earned and 100% of the difference between the MedOx
price and the customer price.               

     B.       Our new Secure Balance(TM) agreement is an exclusive, best
              efforts, 5 year distribution agreement with Secure Health,
                 Inc. within the United States and Canada. The company has had
                an ongoing relationship with Secure Health. Upon the signing
                of the agreement, Secure Health is to receive 500,000 shares
        of our restricted common stock. Ingen will pay a 14%
               commission on the sale price, exclusive of tax and freight.
                  The company will issue 100,000 shares of our restricted common
            stock after the first 5 systems are sold pursuant to the
              contract, another 100,000 such shares upon the sale of the
            10th system and another 50,000 such shares upon the 13th
Secure Balance(TM) system by Secure Health. 

8-K
Last Page of 3
TOC
1st
Previous
Next
↓Bottom
Just 3rd
SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the    
undersigned hereunto duly authorized.                                           

Dated:  December 4, 2006            Ingen Technologies, Inc.                    

             By: /s/ Scott R. Sand
                                    ------------------------------------
              Scott R. Sand,
                                    Chief Executive Officer and Chairman

TABLE OF EXHIBITS                                                               
(All Exhibits have been properly signed by the parties.                         
Original agreements are filed in our offices)                                   

EXHIBIT NO.             DESCRIPTION                                 

      99.1     Distribution Agreement between Ingen Technologies, Inc. and
      MedOx Corporation, dated December 1, 2006, for the
distribution of OxyView(TM).*               

       99.2     Exclusive Distribution Agreement between Ingen Technologies,
                 Inc. and Secure Health, Inc., dated December 1, 2006, for the
distribution of Secure Balance(TM).*        

* filed herewith                                                                

Dates Referenced Herein   and   Documents Incorporated by Reference

				Referenced-On Page
This ‘8-K’ Filing		Date		First		Last			Other Filings
Filed on:		12/5/06							10KSB/A
		12/4/06		3
For Period End:		12/1/06		1		3
									List all Filings